Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Serlopitant improves psoriatic pruritus in phase II trial

17 May 2020

Treatment with serlopitant helps lessen pruritus associated with mild-to-moderate psoriasis, results of a phase II trial have shown. This supports the continued development of serlopitant for this condition.

The investigators examined the efficacy of serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for the treatment of psoriatic pruritus in a total of 204 patients. Participants were randomly assigned to receive either serlopitant 5 mg or placebo daily for 8 weeks.

Adult patients were eligible if they had plaque psoriasis for ≥6 months, plaques covering ≤10 percent of body surface area, pruritus for ≥4 weeks and Worst Itch Numeric Rating Scale (WI-NRS) score ≥7 at the initial screening. The mean age of participants was 47.5 years. More than half (54.2 percent) were women and 85.2 percent were white.

The mean baseline WI-NRS score for serlopitant was 8.3 and for placebo 8.1. The primary endpoint of WI-NRS 4-point response rate at 8 weeks was 33.3 percent for serlopitant compared with 21.1 percent for placebo (p=0.028). The corresponding rates at 4 weeks were 20.8 percent and 11.5 percent (p=0.039).

The incidence of treatment-related adverse events was comparable between serlopitant- and placebo-treated patients (4.9 percent vs 4.0 percent).

This phase II study had certain limitations, including the small sample size and the exclusion of patients with severe psoriasis.

“Pruritus, a common symptom of psoriasis, negatively affects quality of life,” the investigators noted. “[H]owever, treatment of lesional skin does not consistently alleviate psoriatic itch.”

Editor's Recommendations
Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.